BIIB34:BVMF
Biogen Inc BDR
R$Â 184.49
0.00%
(0.00) Siku 1
5 Okt, 16:56:00 GMT -3 · BRL
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya BIIB34...
Fungua
R$Â 185.82
Juu
R$Â 185.82
Chini
R$Â 184.49
Mtaji wa soko
33.04B
Wastani wa kiasi cha mauzo
1.00
Kiasi cha mauzo ya hisa
185.00
Juu kwa wiki 52
R$Â 191.00
Chini kwa wiki 52
R$Â 128.69
Hisa za wawekezaji
147.75M
Idadi ya wafanyakazi
elfu 8
Fungua
R$Â 185.82
Juu
R$Â 185.82
Chini
R$Â 184.49
Mtaji wa soko
33.04B
Wastani wa kiasi cha mauzo
1.00
Kiasi cha mauzo ya hisa
185.00
Juu kwa wiki 52
R$Â 191.00
Chini kwa wiki 52
R$Â 128.69
Hisa za wawekezaji
147.75M
Idadi ya wafanyakazi
elfu 8
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
AD HOC NEWS
·
dakika 43 zilizopita
Biogen reports lupus data while Biogen stock trades at EUR 199.33
Kalkine Media
·
saa 10 zilizopita
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
Wasifu
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Kuhusu Biogen Inc BDR
Afisa Mkuu Mtendaji (CEO)Chris Viehbacher
Wafanyakazielfu 7.5
Lilianzishwa1978
Makao makuuCambridge, Massachusetts, Marekani
Sekta-
Tovutibiogen.com